Syros (SYRS) Announces Research from its Scientific Founders Validates CDK12 and CDK13
- Nasdaq lags peers as Netflix, chip stocks drag; AmEx lifts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Jabil falls after placing CEO on paid leave amid internal investigation
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Syros’ Scientific Founders Publish on First Selective CDK12 and CDK13 Inhibitor as Promising Approach for Treatment of Cancer
August 29, 2016 4:01 PM EDTNovel Small Molecule Approach to Targeting Transcriptional Kinases Validates CDK12 and CDK13 Biology in Cancer
Syros Holds Exclusive Rights to Research, Develop and Commercialize This and Related Selective Small Molecule Inhibitors
Research Findings Published in Nature Chemical Biology
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS) announced today that research from its scientific founders validates CDK12 and CDK13, members of the transcriptional cyclin-dependent kinase family that play a critical role in regulating gene expression, as promising new drug... More